October 31, 2012
GlaxoSmithKline released third quarter results today with Finance Director
saying the pharma group was on course to deliver growth in Q4 and sales "broadly in line" with the previous year.
In a video interview Mr Dingemans said while factors such as costs from disposals and weak European sales had added to a difficult quarter where total sales were down 5%, performances from promoted and new products plus R&D developments meant shareholders saw dividends up 6% year-on-year.
"I think we're pleased with the progress that the growth drivers and the core strategic businesses are making and I think overall that leaves us feeling that we have good momentum going into the fourth quarter."
The interview and transcript are available now on
MerchantCantos produces in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email
or phone +44-207-936-1352.